OverviewChartNewsTraderScreen

Citi Call 215 PGR 16.01.2025/  DE000KJ0SYD2  /

Frankfurt Zert./CITI
2024-05-15  12:14:31 PM Chg.-0.020 Bid2024-05-15 Ask- Underlying Strike price Expiration date Option type
2.130EUR -0.93% 2.130
Bid Size: 30,000		 -
Ask Size: -		 Progressive Corporat... 215.00 USD 2025-01-16 Call
GlobeNewswire 5:15 AM PyroGenesis Announces 2024 First Quarter Results
GlobeNewswire 1:33 AM Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire 05-14 Team, Inc. Reports First Quarter 2024 Results
GlobeNewswire 05-14 Fanatics Sportsbook Cheers on Justin Thomas in his Home State of Kentucky
GlobeNewswire 05-14 Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 05-14 scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 05-14 Norton Rose Fulbright strengthens intellectual property practice with patent lawyer trio
GlobeNewswire 05-14 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associate...
GlobeNewswire 05-14 aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulm...
GlobeNewswire 05-14 Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Tr...
GlobeNewswire 05-14 Troilus Announces Feasibility Study Results for the Gold-Copper Troilus Project: Outlines a Large Sc...
GlobeNewswire 05-14 Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th
GlobeNewswire 05-14 Galaxy Entertainment Group Selected Unaudited Q1 2024 Financial Data
GlobeNewswire 05-14 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment...
GlobeNewswire 05-13 Avalyn Announces Multiple Presentations on its Lead Program, AP01, for Pulmonary Fibrosis and its Ap...
GlobeNewswire 05-13 BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transt...
GlobeNewswire 05-13 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire 05-09 Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st ...
GlobeNewswire 05-09 Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate...
GlobeNewswire 05-08 Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Plan...
GlobeNewswire 05-07 MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-1...
GlobeNewswire 05-06 Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at th...
GlobeNewswire 05-04 The National Fire Sprinkler Association's Class of 2024: Honoring Fire Sprinkler Industry Greats
GlobeNewswire 05-02 PyroGenesis Announces 28-Day Lab Strength Tests Achieve Up to 99.56% Above Compressive Strength Targ...
GlobeNewswire 05-01 Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 A...